Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actelion Adds to PAH Franchise with IV drug from GeneraMedix

This article was originally published in The Pink Sheet Daily

Executive Summary

Buying GeneraMedix’s IV formulation of epoprostenol allows Actelion to leverage its infrastructure and experience in PAH and strengthen its lead in this increasingly crowded market.
Advertisement

Related Content

Actelion Follows Innovation into GP Markets
Actelion Follows Innovation into GP Markets
Review Decision On sNDA For Actelion’s Tracleer Awaits Finalized REMS
Review Decision On sNDA For Actelion’s Tracleer Awaits Finalized REMS
Actelion Launches New PAH Drug In Vietnam; PharmaLink Gets Commercializing Rights
United Therapeutics’ Inhaled Treprostinil May Get Second Quarter 2009 Action Date
Gilead Grabs Cicletanine For PAH From Navitas
Actelion Secures Rights to Nippon Shinyaku’s Hypertension Drug
Actelion Vows To Keep PAH Lead, Despite First-Quarter Dip
Actelion Vows To Keep PAH Lead, Despite First-Quarter Dip

Topics

Advertisement
UsernamePublicRestriction

Register

PS069030

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel